Leerink Partnrs Lowers Earnings Estimates for Schrödinger

Schrödinger, Inc. (NASDAQ:SDGR - Free Report) - Leerink Partnrs decreased their FY2024 EPS estimates for shares of Schrödinger in a research note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now forecasts that the company will earn ($2.11) per share for the year, down from their previous estimate of ($1.99). The consensus estimate for Schrödinger's current full-year earnings is ($2.29) per share. Leerink Partnrs also issued estimates for Schrödinger's Q4 2024 earnings at ($0.09) EPS, FY2025 earnings at ($2.16) EPS and FY2026 earnings at ($2.73) EPS.

A number of other analysts have also recently issued reports on the stock. BMO Capital Markets lifted their target price on shares of Schrödinger from $25.00 to $28.00 and gave the company an "outperform" rating in a research note on Wednesday, November 13th. KeyCorp lifted their price objective on shares of Schrödinger from $25.00 to $27.00 and gave the company an "overweight" rating in a research note on Friday. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $33.10.

Schrödinger Stock Performance

Shares of NASDAQ SDGR traded up $0.26 during trading hours on Friday, hitting $24.67. The stock had a trading volume of 1,284,978 shares, compared to its average volume of 934,424. The firm's 50-day moving average price is $20.71 and its two-hundred day moving average price is $20.08. Schrödinger has a 52 week low of $16.67 and a 52 week high of $33.63. The company has a market capitalization of $1.80 billion, a P/E ratio of -10.54 and a beta of 1.59.

Schrödinger (NASDAQ:SDGR - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.12). Schrödinger had a negative net margin of 91.84% and a negative return on equity of 35.77%. The firm had revenue of $35.30 million for the quarter, compared to analyst estimates of $41.25 million. During the same period in the previous year, the business posted ($0.86) EPS. Schrödinger's revenue for the quarter was down 17.1% on a year-over-year basis.

Institutional Trading of Schrödinger

Several hedge funds have recently added to or reduced their stakes in SDGR. Massachusetts Financial Services Co. MA increased its position in Schrödinger by 58.4% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,945,182 shares of the company's stock worth $36,083,000 after buying an additional 717,059 shares during the period. Rubric Capital Management LP increased its position in Schrödinger by 17.7% during the third quarter. Rubric Capital Management LP now owns 3,685,503 shares of the company's stock worth $68,366,000 after acquiring an additional 555,503 shares during the period. Millennium Management LLC raised its stake in Schrödinger by 2,868.8% during the 2nd quarter. Millennium Management LLC now owns 487,831 shares of the company's stock valued at $9,435,000 after purchasing an additional 471,399 shares during the last quarter. Stephens Investment Management Group LLC boosted its holdings in Schrödinger by 39.6% in the 3rd quarter. Stephens Investment Management Group LLC now owns 1,539,870 shares of the company's stock valued at $28,565,000 after purchasing an additional 436,789 shares during the period. Finally, Barclays PLC boosted its holdings in Schrödinger by 421.6% in the 3rd quarter. Barclays PLC now owns 107,554 shares of the company's stock valued at $1,995,000 after purchasing an additional 86,933 shares during the period. Institutional investors own 79.05% of the company's stock.

Schrödinger Company Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.